Toxicological studies of

Gemcitabine Medicinal herb O.s., Orthosiphon stamineus Orthosiphon stamineus Pancreatic cancer Rosmarinic acid

Journal

Journal of advanced research
ISSN: 2090-1232
Titre abrégé: J Adv Res
Pays: Egypt
ID NLM: 101546952

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 05 01 2018
revised: 16 04 2018
accepted: 08 05 2018
entrez: 25 12 2018
pubmed: 26 12 2018
medline: 26 12 2018
Statut: epublish

Résumé

Pancreatic cancer has the highest mortality rate among cancers due to its aggressive biology and lack of effective treatment. Gemcitabine, the first line anticancer drug has reduced efficacy due to acquired resistance. The current study evaluates the toxicological effects of

Identifiants

pubmed: 30581613
doi: 10.1016/j.jare.2018.05.006
pii: S2090-1232(18)30061-4
pmc: PMC6300433
doi:

Types de publication

Journal Article

Langues

eng

Pagination

59-68

Références

J Immunol. 1999 Nov 15;163(10):5686-92
pubmed: 10553099
Regul Toxicol Pharmacol. 2000 Aug;32(1):56-67
pubmed: 11029269
Am J Respir Crit Care Med. 2005 Feb 1;171(3):261-8
pubmed: 15502109
J Immunol. 2005 Jul 15;175(2):1224-31
pubmed: 16002726
J Ethnopharmacol. 2006 May 24;105(3):374-9
pubmed: 16413715
J Immunol. 2007 Jul 1;179(1):708-14
pubmed: 17579094
Toxicol Pathol. 2007 Aug;35(5):751-5
pubmed: 17849358
Trop Biomed. 2008 Apr;25(1):9-16
pubmed: 18600199
Int Immunopharmacol. 2009 Jan;9(1):70-9
pubmed: 18976720
J Burn Care Res. 2010 Jan-Feb;31(1):158-75
pubmed: 20061852
J Ethnopharmacol. 2011 Jan 27;133(2):358-63
pubmed: 20937371
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
PLoS One. 2013;8(3):e59918
pubmed: 23536895
Carcinogenesis. 2013 Oct;34(10):2361-9
pubmed: 23803690
Ther Drug Monit. 2014 Aug;36(4):413-22
pubmed: 24452064
Anticancer Res. 2014 Feb;34(2):943-8
pubmed: 24511037
Eur J Pharmacol. 2014 Oct 15;741:8-16
pubmed: 25084222
Int Endod J. 2015 Jul;48(7):705-16
pubmed: 25311745
Blood. 2015 Jan 22;125(4):616-8
pubmed: 25414441
Support Care Cancer. 2015 Jun;23(6):1795-806
pubmed: 25471177
J Clin Oncol. 2015 Mar 20;33(9):1060-6
pubmed: 25605849
Biosci Trends. 2015 Feb;9(1):16-34
pubmed: 25787906
Lancet Oncol. 2015 Jul;16(7):763-74
pubmed: 26045340
Eur J Cancer. 2015 Aug;51(12):1546-54
pubmed: 26049689
J Clin Oncol. 2015 Aug 10;33(23):2563-77
pubmed: 26101248
BMC Complement Altern Med. 2015 Oct 14;15:360
pubmed: 26467526
Lancet. 2016 Feb 6;387(10018):545-57
pubmed: 26615328
Int Sch Res Notices. 2015 Jan 26;2015:473296
pubmed: 27347522
BMC Complement Altern Med. 2016 Nov 24;16(1):480
pubmed: 27881135

Auteurs

Ashwaq H S Yehya (AHS)

Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang 11800, Malaysia.

Muhammad Asif (M)

Faculty of Pharmaceutical Sciences, Government College University, Faisalabad 38000, Pakistan.

Gurjeet Kaur (G)

Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang 11800, Malaysia.

Loiy E A Hassan (LEA)

EMAN Testing and Research Laboratories, Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia.

Fouad S R Al-Suede (FSR)

EMAN Testing and Research Laboratories, Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia.

Amin M S Abdul Majid (AMS)

EMAN Testing and Research Laboratories, Department of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia.
ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University, Australia.

Chern E Oon (CE)

Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang 11800, Malaysia.

Classifications MeSH